AAD 2024: Lebrikizumab Exhibits Safety and Efficacy Among Atopic Dermatitis Patients of Color
Interim results reveal significant improvements in disease extent and severity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.